Welcome to our dedicated page for ImmunityBio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmunityBio, Inc. filings document the formal reporting record for a commercial-stage immunotherapy company with Nasdaq-listed common stock. Form 8-K reports furnish operating results, ANKTIVA product revenue updates, regulatory authorizations for ANKTIVA with BCG in NMIBC, FDA promotional-compliance correspondence, and material agreements including revenue interest purchase agreement amendments and convertible promissory note amendments.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data, and shareholder voting matters. The filings also describe capital structure and financing obligations, related-party arrangements, and risk factors tied to clinical development, regulatory review, manufacturing and supply, commercialization, reimbursement, competition, and market acceptance.
ImmunityBio, Inc. director Cheryl Cohen reported an exercise-and-sale transaction involving the company’s common stock. On 2026-07-02, she sold 131,210 shares in an open‑market transaction at a weighted average price of $9.5034 per share, under a pre‑arranged Rule 10b5-1 trading plan.
On the same date, Cohen exercised stock options to acquire 55,979 common shares at an exercise price of $2.98 per share, reducing her option position while increasing her direct shareholdings before the sale. Following these transactions, she directly holds 125,386 common shares and 111,958 stock options.
ImmunityBio director Christobel Selecky exercised stock options and sold the resulting shares. She exercised options covering 124,414 shares at $2.99 per share and 35,064 shares at $2.98 per share, then sold 159,478 shares of Common Stock in open-market transactions at a weighted average price of $9.0236 per share, within a range of $9.00 to $9.07. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. After these transactions, the filing shows she holds no remaining common shares or related options.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 notice to sell common stock listed on NASDAQ. The filing lists an intended sale tied to an exercise of stock options for 55,979 shares dated 07/02/2026 and an entry for 75,231 restricted stock units dated 06/06/2021.
ImmunityBio, Inc. director Christobel Selecky exercised stock options and sold the resulting shares in pre-planned trades. On June 29–30, 2026, she exercised options for a total of 96,722 shares of Common Stock at exercise prices between $2.84 and $2.99 per share and sold 96,722 shares in open-market transactions, including 95,722 shares at a weighted-average price of $9.0075 and 1,000 shares at $9.00 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating they were pre-scheduled rather than discretionary. Following these transactions, Selecky reported no directly held Common Stock, while retaining stock options to purchase additional shares at the disclosed exercise prices and expiration dates.
The issuer reports a proposed resale of 159,478 common shares related to an exercise of stock options to be settled for cash on 07/01/2026. The filing also records recent 10b5-1 sales of 95,722 shares and 1,000 shares on 06/29/2026 and 06/30/2026, respectively, with proceeds shown.
Issuer submitted a Form 144 disclosing a proposed sale and recent transactions in Common Stock.
The filing shows an exercise of 1,000 shares settled for cash on 06/30/2026, and prior 10b5-1 sales by Christobel Selecky of 95,722 shares on 06/29/2026 for $862,212.63.
ImmunityBio, Inc. director Barry J. Simon reported an open-market sale of common stock. On June 24, 2026, he sold 25,000 shares at a weighted average price of $7.8763 per share, in a trade executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. After this transaction, he continues to hold 2,802,788 shares of ImmunityBio common stock directly.
ImmunityBio director Michael D. Blaszyk received a grant of stock options covering 65,600 shares of common stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.
According to the award terms, subject to his continuing to be a Service Provider under ImmunityBio’s 2025 Equity Incentive Plan, 100% of the shares subject to the option will vest on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting.
ImmunityBio director Wendel Bruce received a new stock option grant as part of his compensation. He was awarded options covering 65,600 shares of ImmunityBio common stock at an exercise price of $7.25 per share, with no cash paid at grant.
These options vest 100% on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting, as long as he continues as a service provider under the company’s 2025 Equity Incentive Plan. The options expire on June 9, 2036, giving a long-term incentive tied to the company’s share price.